ADA inhibits the PI3K/Akt pathway and its downstream target NF-κB in melanoma cells, reduces the expression of the anti-apoptotic proteins c-FLIP, XIAP and Bcl-2, and promotes the activation of caspase-3 and PARP to induce apoptosis [145]. The gene discussed is BCL2; the disease is melanoma.